Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
Skip navigation

A trial looking at RAD001 for kidney cancer that has spread - RAPTOR

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

This trial is looking at RAD001 (also called everolimus and Afinitor) for kidney cancer that has spread to other parts of the body.

The most common type of kidney cancer in adults is renal cell cancer. This trial is for people who have a particular type of renal cell cancer called papillary renal cell cancer.

Doctors often treat kidney cancer with interferon and interleukin 2. But doctors are always looking for new ways to treat people with kidney cancer.

Everolimus is a type of treatment called a biological therapy. It works by blocking the action of a protein called mTOR. The mTOR protein controls other proteins that cancer cells need in order to grow. The researchers hope this will help to stop or slow the growth of the cancer.

We know from research that everolimus has helped people with other types of cancer. The researchers think it may also help people with advanced kidney cancer.

The aims of this trial are to find out

  • If everolimus can help people with advanced kidney cancer
  • How safe it is to give everolimus to people with advanced kidney cancer

Recruitment

Start 01/07/2009
End 04/08/2011

Phase

Phase 2

Who can enter

You can enter this trial if you

  • Have a type of kidney cancer called papillary renal cell cancer type 1 or 2 that has spread
  • Have at least 1 tumour that can be measured on a scan
  • Have satisfactory blood test results
  • Are fully active and able to look after yourself, apart from doing heavy physical work (performance status 0, 1)
  • Are willing to use reliable contraception if there is a chance that you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if

  • Your cancer has spread to your spinal cord or brain (central nervous system) and your symptoms are not controlled
  • You have had radiotherapy in the last 4 weeks
  • You have had radiotherapy to control bone pain in the last 2 weeks
  • You have already had treatment that reaches the whole body (systemic treatment) for renal cell cancer that has spread, such as sunitinib, sorafenib or bevacizumab
  • You have had everolimus, or similar drugs such as temsirolimus, before
  • You are allergic to everolimus, or similar drugs, and their ingredients
  • You are taking 10mg or more of steroid tablets daily (please note, it is important that you do not stop taking steroids unless your doctor tells you to)
  • You have had another drug as a part of a clinical trial in the last 4 weeks
  • You have had another cancer in the last 3 years, apart from non melanoma skin cancer or carcinoma in situ of the cervix
  • You have heart problems or had a heart attack in the last 6 months
  • You have liver problems
  • You have serious breathing problems
  • You have diabetes that is not controlled with medication
  • You have an infection
  • You have bleeding problems
  • You are known to be HIV positive
  • You have another serious medical condition that could affect you taking part in the trial

Trial design

This is an international phase 2 trial. It will recruit 12 people in the UK. Everyone taking part in this trial will have everolimus.

Everolimus is a tablet. You take 2 tablets once a day at the same time each day. You take them on an empty stomach or with a light, low fat meal such as cereal with fat free milk, toast or bagel with a fat free spread.

Exactly how long you have treatment for, will depend on your side effects and whether the treatment is still helping to control your cancer.

You cannot eat certain fruits, or drink their juice, while having everolimus. This is because they can interfere with the way it works in your body. These fruits include grapefruit, Seville oranges and star fruit.

Hospital visits

You will see the doctor and have some tests before you start treatment. These tests include

You see the doctor

  • Every 2 weeks for 3 months
  • Every month for up to 2 years

Every 8 weeks you have a CT scan or MRI scan.

Side effects

The most common side effects of everolimus are

You can find more about everolimus on CancerHelp UK.

Location of trial

CLOSED

For more information

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you need to print this page and take it to your own doctor to discuss.

Find out how to join a trial or contact our cancer information nurses for other questions about cancer by phone (0808 800 4040), by email, or at

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Chief Investigator

Dr Paul Nathan

Supported by

Experimental Cancer Medicine Centre (ECMC)
Novartis
Rate this page:
Submit rating
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 4 August 2011